News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Effect of Genzyme Corporation (GENZ)'s LEMTRADA Maintained in Patients Beyond Two-Year Pivotal MS Studies


3/28/2013 9:15:49 AM

MISSISSAUGA, ON, March 28, 2013 /CNW/ - Genzyme, a Sanofi Company announced interim results from the first year of the extension study of LEMTRADA™ (alemtuzumab), being developed for the treatment for multiple sclerosis (MS). The data were presented March 21 at the American Academy of Neurology meeting in San Diego, California.

Read at Canada NewsWire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES